Antiviral agents: Selected publications
Harald Labischinski und Helga Rübsamen-Waigmann
Prospects and challenges in Anti-infective research and development: new drugs and approaches in:
Current Opinion in Pharmacology, 2008, 8: 519-521.
H. Zimmermann, G. Hewlett, and H. Rübsamen-Waigmann
Other Inhibitors of Viral Enzymes and Functions
H.-G. Kräusslich, R. Bartenschlager (eds.), Antiviral Strategies, Handbook of Experimental 155, Pharmacology 189, © Springer-Verlag Berlin Heidelberg 2009
Lischka P, Hewlett G, Wunberg T, Baumeister J, Paulsen D, Goldner T, Ruebsamen-Schaeff H, Zimmermann H.
In vitro and in vivo Activities of the novel Anti-Cytomegalovirus Compound AIC246
Antimicrob Agents Chemother. 2010 Jan 4.
Lischka P, Zimmermann H.
Antiviral strategies to combat cytomegalovirus infections in transplant recipients.
Curr Opin Pharmacol. 2008 Oct;8(5):541-8. Epub 2008 Aug 25. Review.
Biswas S, Tiley LS, Zimmermann H, Birkmann A, Field HJ
Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity.
Antiviral Res. 2008 Oct;80(1):81-5. Epub 2008 May 16.
Kaufman HE, Varnell ED, Gebhardt BM, Thompson HW, Atwal E, Rübsamen-Waigmann H, Kleymann G.
Efficacy of a Helicase-Primase Inhibitor in Animal Models of Ocular Herpes Simplex Virus Type 1 Infection. J Ocul Pharmacol Ther. 2008 Jan 17; [Epub ahead of print]
Baumeister J, Fischer R, Eckenberg P, Henninger K, Ruebsamen-Waigmann H, Kleymann G.
Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease. Antivir Chem Chemother. 2007;18(1):35-48.
Kehlenbeck S , Betz U , Birkmann A , Fast B , Göller AH , Henninger K , Lowinger T , Marrero D , Paessens A , Paulsen D , Pevzner V , Schohe-Loop R , Tsujishita H , Welker R , Kreuter J , Rübsamen-Waigmann H , Dittmer F .
Dihydroxythiophenes are novel potent inhibitors of human immunodeficiency virus integrase with a diketo acid-like pharmacophore. J Virol. 2006 Jul;80(14):6883-94.
Deres K, Schröder CH, Paessens A, Goldmann S, Hacker HJ, Weber O, Krämer T, Niewöhner U, Pleiss U, Stoltefuss J, Graef E, Koletzki D, Masantschek RN, Reimann A, Jaeger R, Gross R, Beckermann B, Schlemmer KH, Haebich D, Rübsamen-Waigmann H.
Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science. 2003 Feb 7;299(5608):893-6.
Betz UA, Fischer R, Kleymann G, Hendrix M, Rübsamen-Waigmann H.
Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. Antimicrob Agents Chemother. 2002 Jun;46(6):1766-72.
Weber O, Schlemmer KH, Hartmann E, Hagelschuer I, Paessens A, Graef E, Deres K, Goldmann S, Niewoehner U, Stoltefuss J, Haebich D, Ruebsamen-Waigmann H, Wohlfeil S.
Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antiviral Res. 2002 May;54(2):69-78.
Kleymann G, Fischer R, Betz UA, Hendrix M, Bender W, Schneider U, Handke G, Eckenberg P, Hewlett G, Pevzner V, Baumeister J, Weber O, Henninger K, Keldenich J, Jensen A, Kolb J, Bach U, Popp A, Mäben J, Frappa I, Haebich D, Lockhoff O, Rübsamen-Waigmann H.
New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat med. 2002 Apr;8(4):392-8.
Reefschlaeger J, Bender W, Hallenberger S, Weber O, Eckenberg P, Goldmann S, Haerter M, Buerger I, Trappe J, Herrington JA, Haebich D, Ruebsamen-Waigmann H.
Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. J Antimicrob Chemother. 2001 Dec;48(6):757-67.
Buerger I, Reefschlaeger J, Bender W, Eckenberg P, Popp A, Weber O, Graeper S, Klenk HD, Ruebsamen-Waigmann H, Hallenberger S.
A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J Virol. 2001 Oct;75(19):9077-86.
